- Press releases
- Country: United States
PAQ Therapeutics Presents First Clinical Data for PT0253, a Selective KRAS G12D Degrader, Showing a Differentiated Safety Profile and Antitumor Activity at ENA 2026
– No dose-limiting toxicities observed across doses from 10 to 750 mg, with no PT0253-specific pre-treatment prophylaxis required – – Monotherapy antitumor activity observed in colorectal and pancreatic cancers, including a partial response in a patient previously treated with a...